Hopkins scientists test 'One-Two Punch' drug combo to outsmart resistant prostate cancer
NCT ID NCT06059118
Summary
This study is testing a new treatment sequence for men whose advanced prostate cancer has progressed despite standard hormone therapy. The approach cycles through three drugs—DFMO, high-dose testosterone, and enzalutamide—over 119-day periods, aiming to control cancer growth and delay progression. It is for patients who have cancer that has spread but are not experiencing significant pain from it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.